SCHEMBL2421067

SCHEMBL2421067

O=C(Oc1ccccc1C1CCC[N]1)N1CCCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.51
ALDH1A1 P00352 4/20 0.51
GAA P10253 2/20 0.51
TSHR P16473 1/20 0.47
TP53 P04637 3/20 0.44
NPSR1 Q6W5P4 3/20 0.44
TDP1 Q9NUW8 2/20 0.44
NPC1 O15118 4/20 0.43
RAB9A P51151 3/20 0.43
LMNA P02545 3/20 0.43
POLB P06746 2/20 0.43
HPGD P15428 2/20 0.42
NCEH1 Q6PIU2 2/20 0.42
CYP1A2 P05177 2/20 0.42
CYP2C19 P33261 2/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
HTT P42858 1/20 0.42
CASP3 P42574 1/20 0.42
SENP8 Q96LD8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2424506 1.00 SMN1; SMN2 (0.51) SMN1; SMN2ALDH1A1GAATSHRTP53
SCHEMBL2421860 1.00 SMN1; SMN2 (0.51) SMN1; SMN2ALDH1A1GAATSHRTP53
SCHEMBL2423002 0.90 TP53 (0.60) SMN1; SMN2ALDH1A1GAATSHRTP53
SCHEMBL2419710 0.90 TP53 (0.60) SMN1; SMN2ALDH1A1GAATSHRTP53
SCHEMBL22165568 0.80 SMN1; SMN2 (0.59) SMN1; SMN2ALDH1A1GAATSHRTP53
SCHEMBL2172962 0.78 HPGD (0.44) SMN1; SMN2ALDH1A1GAATSHRTDP1
SCHEMBL2173932 0.78 HPGD (0.44) SMN1; SMN2ALDH1A1GAATSHRTDP1
SCHEMBL2175854 0.77 ACHE (0.48) TSHRNPC1RAB9ANCEH1
SCHEMBL2175046 0.77 ACHE (0.48) TSHRNPC1RAB9ANCEH1
SCHEMBL2172227 0.77 ACHE (0.44) ALDH1A1GAALMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853243-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2014-10-07 US disclosed
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES INCYTE CORPORATION 2011-09-15 US disclosed
EP-2264030-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases Incyte Corporation (US) 2010-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES MMP25, MMP14, MMP9 SMN1; SMN2 4489/4885ALDH1A1 673/4885GAA 136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.